A macrophage-nanozyme delivery system for Parkinson's disease

Elena V. Batrakova, Shu Li, Ashley D. Reynolds, R Lee Mosley, Tatiana K Bronich, Alexander V. Kabanov, Howard Eliot Gendelman

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Selective delivery of antioxidants to the substantia nigra pars compacta (SNpc) during Parkinson's disease (PD) can potentially attenuate oxidative stress and as such increase survival of dopaminergic neurons. To this end, we developed a bone-marrow-derived macrophage (BMM) system to deliver catalase to PD-affected brain regions in an animal model of human disease. To preclude BMM-mediated enzyme degradation, catalase was packaged into a block ionomer complex with a cationic block copolymer, polyethyleneimine-poly(ethylene glycol) (PEI-PEG). The self-assembled catalase/PEI-PEG complexes, "nanozymes" , were ca. 60 to 100 nm in size, stable in pH and ionic strength, and retained antioxidant activities. Cytotoxicity was negligible over a range of physiologic nanozyme concentrations. Nanozyme particles were rapidly, 40-60 min, taken up by BMM, retained catalytic activity, and released in active form for greater than 24 h. In contrast, "naked" catalase was rapidly degraded. The released enzyme decomposed microglial hydrogen peroxide following nitrated alpha-synuclein or tumor necrosis factor alpha activation. Following adoptive transfer of nanozyme-loaded BMM to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine- intoxicated mice, ca. 0.6% of the injected dose were found in brain. We conclude that cell-mediated delivery of nanozymes can reduce oxidative stress in laboratory and animal models of PD.

Original languageEnglish (US)
Pages (from-to)1498-1506
Number of pages9
JournalBioconjugate Chemistry
Volume18
Issue number5
DOIs
StatePublished - Sep 1 2007

Fingerprint

Macrophages
Catalase
Parkinson Disease
Bone
Polyethyleneimine
Oxidative stress
Ethylene Glycol
Antioxidants
Polyethylene glycols
Brain
Animals
Oxidative Stress
Enzymes
Animal Disease Models
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
alpha-Synuclein
Ionomers
Adoptive Transfer
Dopaminergic Neurons
Cytotoxicity

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

A macrophage-nanozyme delivery system for Parkinson's disease. / Batrakova, Elena V.; Li, Shu; Reynolds, Ashley D.; Mosley, R Lee; Bronich, Tatiana K; Kabanov, Alexander V.; Gendelman, Howard Eliot.

In: Bioconjugate Chemistry, Vol. 18, No. 5, 01.09.2007, p. 1498-1506.

Research output: Contribution to journalArticle

Batrakova, Elena V. ; Li, Shu ; Reynolds, Ashley D. ; Mosley, R Lee ; Bronich, Tatiana K ; Kabanov, Alexander V. ; Gendelman, Howard Eliot. / A macrophage-nanozyme delivery system for Parkinson's disease. In: Bioconjugate Chemistry. 2007 ; Vol. 18, No. 5. pp. 1498-1506.
@article{9e5872fac7a8469c866a8b9bd3cba730,
title = "A macrophage-nanozyme delivery system for Parkinson's disease",
abstract = "Selective delivery of antioxidants to the substantia nigra pars compacta (SNpc) during Parkinson's disease (PD) can potentially attenuate oxidative stress and as such increase survival of dopaminergic neurons. To this end, we developed a bone-marrow-derived macrophage (BMM) system to deliver catalase to PD-affected brain regions in an animal model of human disease. To preclude BMM-mediated enzyme degradation, catalase was packaged into a block ionomer complex with a cationic block copolymer, polyethyleneimine-poly(ethylene glycol) (PEI-PEG). The self-assembled catalase/PEI-PEG complexes, {"}nanozymes{"} , were ca. 60 to 100 nm in size, stable in pH and ionic strength, and retained antioxidant activities. Cytotoxicity was negligible over a range of physiologic nanozyme concentrations. Nanozyme particles were rapidly, 40-60 min, taken up by BMM, retained catalytic activity, and released in active form for greater than 24 h. In contrast, {"}naked{"} catalase was rapidly degraded. The released enzyme decomposed microglial hydrogen peroxide following nitrated alpha-synuclein or tumor necrosis factor alpha activation. Following adoptive transfer of nanozyme-loaded BMM to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine- intoxicated mice, ca. 0.6{\%} of the injected dose were found in brain. We conclude that cell-mediated delivery of nanozymes can reduce oxidative stress in laboratory and animal models of PD.",
author = "Batrakova, {Elena V.} and Shu Li and Reynolds, {Ashley D.} and Mosley, {R Lee} and Bronich, {Tatiana K} and Kabanov, {Alexander V.} and Gendelman, {Howard Eliot}",
year = "2007",
month = "9",
day = "1",
doi = "10.1021/bc700184b",
language = "English (US)",
volume = "18",
pages = "1498--1506",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - A macrophage-nanozyme delivery system for Parkinson's disease

AU - Batrakova, Elena V.

AU - Li, Shu

AU - Reynolds, Ashley D.

AU - Mosley, R Lee

AU - Bronich, Tatiana K

AU - Kabanov, Alexander V.

AU - Gendelman, Howard Eliot

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Selective delivery of antioxidants to the substantia nigra pars compacta (SNpc) during Parkinson's disease (PD) can potentially attenuate oxidative stress and as such increase survival of dopaminergic neurons. To this end, we developed a bone-marrow-derived macrophage (BMM) system to deliver catalase to PD-affected brain regions in an animal model of human disease. To preclude BMM-mediated enzyme degradation, catalase was packaged into a block ionomer complex with a cationic block copolymer, polyethyleneimine-poly(ethylene glycol) (PEI-PEG). The self-assembled catalase/PEI-PEG complexes, "nanozymes" , were ca. 60 to 100 nm in size, stable in pH and ionic strength, and retained antioxidant activities. Cytotoxicity was negligible over a range of physiologic nanozyme concentrations. Nanozyme particles were rapidly, 40-60 min, taken up by BMM, retained catalytic activity, and released in active form for greater than 24 h. In contrast, "naked" catalase was rapidly degraded. The released enzyme decomposed microglial hydrogen peroxide following nitrated alpha-synuclein or tumor necrosis factor alpha activation. Following adoptive transfer of nanozyme-loaded BMM to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine- intoxicated mice, ca. 0.6% of the injected dose were found in brain. We conclude that cell-mediated delivery of nanozymes can reduce oxidative stress in laboratory and animal models of PD.

AB - Selective delivery of antioxidants to the substantia nigra pars compacta (SNpc) during Parkinson's disease (PD) can potentially attenuate oxidative stress and as such increase survival of dopaminergic neurons. To this end, we developed a bone-marrow-derived macrophage (BMM) system to deliver catalase to PD-affected brain regions in an animal model of human disease. To preclude BMM-mediated enzyme degradation, catalase was packaged into a block ionomer complex with a cationic block copolymer, polyethyleneimine-poly(ethylene glycol) (PEI-PEG). The self-assembled catalase/PEI-PEG complexes, "nanozymes" , were ca. 60 to 100 nm in size, stable in pH and ionic strength, and retained antioxidant activities. Cytotoxicity was negligible over a range of physiologic nanozyme concentrations. Nanozyme particles were rapidly, 40-60 min, taken up by BMM, retained catalytic activity, and released in active form for greater than 24 h. In contrast, "naked" catalase was rapidly degraded. The released enzyme decomposed microglial hydrogen peroxide following nitrated alpha-synuclein or tumor necrosis factor alpha activation. Following adoptive transfer of nanozyme-loaded BMM to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine- intoxicated mice, ca. 0.6% of the injected dose were found in brain. We conclude that cell-mediated delivery of nanozymes can reduce oxidative stress in laboratory and animal models of PD.

UR - http://www.scopus.com/inward/record.url?scp=34648843409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648843409&partnerID=8YFLogxK

U2 - 10.1021/bc700184b

DO - 10.1021/bc700184b

M3 - Article

C2 - 17760417

AN - SCOPUS:34648843409

VL - 18

SP - 1498

EP - 1506

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 5

ER -